Karen E. Weck

8.5k total citations · 1 hit paper
93 papers, 4.7k citations indexed

About

Karen E. Weck is a scholar working on Genetics, Oncology and Molecular Biology. According to data from OpenAlex, Karen E. Weck has authored 93 papers receiving a total of 4.7k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Genetics, 19 papers in Oncology and 18 papers in Molecular Biology. Recurrent topics in Karen E. Weck's work include Pharmacogenetics and Drug Metabolism (18 papers), Genomics and Rare Diseases (16 papers) and Cancer Genomics and Diagnostics (11 papers). Karen E. Weck is often cited by papers focused on Pharmacogenetics and Drug Metabolism (18 papers), Genomics and Rare Diseases (16 papers) and Cancer Genomics and Diagnostics (11 papers). Karen E. Weck collaborates with scholars based in United States, China and Netherlands. Karen E. Weck's co-authors include Herbert W. Virgin, Samuel H. Speck, Albert J. Dal Canto, Phil Latreille, P Wamsley, Parmjeet Randhawa, Ron Shapiro, Abhay Vats, Zhen‐Yu Chen and Houda Hachad and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Karen E. Weck

91 papers receiving 4.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Complete sequence and genomic analysis of murine gammaherpesvirus 68

1997 647 citations Karen E. Weck et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Karen E. Weck United States	36	2.2k	1.9k	738	691	541	93	4.7k
Thomas Urban United States	31	1.0k 0.5×	2.7k 1.5×	370 0.5×	907 1.3×	505 0.9×	65	5.9k
Tom H. Karlsen Norway	54	1.2k 0.5×	3.5k 1.9×	1.2k 1.7×	1.8k 2.6×	318 0.6×	170	9.5k
Cord Langner Austria	48	2.6k 1.2×	2.4k 1.3×	2.0k 2.7×	1.8k 2.6×	382 0.7×	223	8.7k
Gilles Paintaud France	43	965 0.4×	1.5k 0.8×	1.7k 2.3×	948 1.4×	241 0.4×	194	6.3k
Péter Fritz Germany	39	2.0k 0.9×	440 0.2×	966 1.3×	1.8k 2.6×	222 0.4×	133	6.4k
Daniela Basso Italy	42	1.7k 0.8×	963 0.5×	563 0.8×	1.6k 2.3×	600 1.1×	294	6.5k
Francesco Callea Italy	33	776 0.3×	4.5k 2.4×	303 0.4×	930 1.3×	316 0.6×	158	8.0k
Andrew D. Clouston Australia	57	2.4k 1.1×	4.9k 2.6×	581 0.8×	1.4k 2.0×	280 0.5×	197	11.4k
Morikazu Onji Japan	47	639 0.3×	4.0k 2.1×	304 0.4×	761 1.1×	405 0.7×	313	7.3k
Jorge Quiroga Spain	42	827 0.4×	2.3k 1.2×	349 0.5×	573 0.8×	155 0.3×	190	5.4k

Countries citing papers authored by Karen E. Weck

Since Specialization

Citations

This map shows the geographic impact of Karen E. Weck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karen E. Weck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karen E. Weck more than expected).

Fields of papers citing papers by Karen E. Weck

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karen E. Weck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karen E. Weck. The network helps show where Karen E. Weck may publish in the future.

Co-authorship network of co-authors of Karen E. Weck

This figure shows the co-authorship network connecting the top 25 collaborators of Karen E. Weck. A scholar is included among the top collaborators of Karen E. Weck based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karen E. Weck. Karen E. Weck is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Pratt, Victoria M., Larisa H. Cavallari, Andrea Gaedigk, et al.. (2024). DPYD Genotyping Recommendations. Journal of Molecular Diagnostics. 26(10). 851–863. 21 indexed citations

Sanoff, Hanna K., Allison M. Deal, Jai N. Patel, et al.. (2024). A phase II trial of UGT1A1 genotype-guided FOLFIRI plus bevacizumab as first-line therapy for advanced, unresectable colorectal cancer. The Oncologist. 29(9). 786–793. 1 indexed citations

Gilmore, Kelly L., et al.. (2023). Association of deep phenotyping with diagnostic yield of prenatal exome sequencing for fetal brain abnormalities. Genetics in Medicine. 25(10). 100915–100915. 8 indexed citations

Pratt, Victoria M., Larisa H. Cavallari, Andrea Gaedigk, et al.. (2023). CYP3A4 and CYP3A5 Genotyping Recommendations. Journal of Molecular Diagnostics. 25(9). 619–629. 33 indexed citations

Pratt, Victoria M., Larisa H. Cavallari, Andria L. Del Tredici, et al.. (2021). Recommendations for Clinical CYP2D6 Genotyping Allele Selection. Journal of Molecular Diagnostics. 23(9). 1047–1064. 97 indexed citations

Sriramoju, Vindhya, Joseph S. Rossi, Megan M. Clarke, et al.. (2019). Frequency and clinical outcomes of CYP2C19 genotype-guided escalation and de-escalation of antiplatelet therapy in a real-world clinical setting. Genetics in Medicine. 22(1). 160–169. 39 indexed citations

Pratt, Victoria M., Larisa H. Cavallari, Andria L. Del Tredici, et al.. (2019). Recommendations for Clinical CYP2C9 Genotyping Allele Selection: A Joint Recommendation of the Association for Molecular Pathology and College of American Pathologists. Publisher. 12 indexed citations

Pratt, Victoria M., Andria L. Del Tredici, Houda Hachad, et al.. (2018). Recommendations for Clinical CYP2C19 Genotyping Allele Selection. Journal of Molecular Diagnostics. 20(3). 269–276. 141 indexed citations

Skinner, Debra, Myra I. Roche, Karen E. Weck, et al.. (2018). “Possibly positive or certainly uncertain?”: participants’ responses to uncertain diagnostic results from exome sequencing. Genetics in Medicine. 20(3). 313–319. 35 indexed citations

10.

McRee, Autumn J., P. Kelly Marcom, Dominic T. Moore, et al.. (2017). A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast Cancer. Clinical Breast Cancer. 18(4). 289–297. 21 indexed citations

11.

Deal, Allison M., Christine M. Walko, Joseph G. Ibrahim, et al.. (2017). Comprehensive assessment of cytochromes P450 and transporter genetics with endoxifen concentration during tamoxifen treatment. Pharmacogenetics and Genomics. 27(11). 402–409. 13 indexed citations

12.

Oglesbee, Devin, Tina M. Cowan, Marzia Pasquali, et al.. (2017). CAP/ACMG proficiency testing for biochemical genetics laboratories: a summary of performance. Genetics in Medicine. 20(1). 83–90. 6 indexed citations

13.

Press, Richard D., et al.. (2016). Highly accurate molecular genetic testing for HFE hereditary hemochromatosis: results from 10 years of blinded proficiency surveys by the College of American Pathologists. Genetics in Medicine. 18(12). 1206–1213. 4 indexed citations

14.

Lyon, Elaine, Iris Schrijver, Karen E. Weck, et al.. (2014). Molecular genetic testing for cystic fibrosis: laboratory performance on the College of American Pathologists external proficiency surveys. Genetics in Medicine. 17(3). 219–225. 9 indexed citations

15.

Shapiro, Adam J., Karen E. Weck, Margaret Rosenfeld, et al.. (2014). Cri du Chat Syndrome and Primary Ciliary Dyskinesia: A Common Genetic Cause on Chromosome 5p. The Journal of Pediatrics. 165(4). 858–861. 7 indexed citations

16.

Tarczy‐Hornoch, Peter, Laura M. Amendola, Samuel Aronson, et al.. (2013). A survey of informatics approaches to whole-exome and whole-genome clinical reporting in the electronic health record. Genetics in Medicine. 15(10). 824–832. 49 indexed citations

17.

Hayes, D. Neil, Tawee Tanvetyanon, Monika K. Krzyzanowska, et al.. (2012). Phase II Efficacy and Pharmacogenomic Study of Selumetinib (AZD6244; ARRY-142886) in Iodine-131 Refractory Papillary Thyroid Carcinoma with or without Follicular Elements. Clinical Cancer Research. 18(7). 2056–2065. 120 indexed citations

18.

Berg, Jonathan S., James P. Evans, Margaret W. Leigh, et al.. (2011). Next generation massively parallel sequencing of targeted exomes to identify genetic mutations in primary ciliary dyskinesia: Implications for application to clinical testing. Genetics in Medicine. 13(3). 218–229. 41 indexed citations

19.

Booker, Jessica K., et al.. (2009). Validation of Clinical Testing for Warfarin Sensitivity. Journal of Molecular Diagnostics. 11(3). 216–225. 38 indexed citations

20.

Jones, Dan, Suzanne Kamel‐Reid, David W. Bahler, et al.. (2008). Laboratory Practice Guidelines for Detecting and Reporting BCR-ABL Drug Resistance Mutations in Chronic Myelogenous Leukemia and Acute Lymphoblastic Leukemia. Journal of Molecular Diagnostics. 11(1). 4–11. 45 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact